Clinical Trial

Testing Dermatitis Medication in Healthy Subjects

Study Description

A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis

The main purpose of this study is to investigate the safety, tolerability, and efficacy of the study drug known as LY3454738 in healthy participants and participants with atopic dermatitis. The study has three parts. Each participant will enroll in one part. The study will last 12 to 24 weeks, depending on part.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - LY3454738

Administered IV

Drug - LY3454738

Administered SC

Drug - Placebo

Administered IV

Additional Information

Official Study Title

Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis

Clinical Trial ID

NCT03750643

ParticipAid ID

bqxAra